Department of Anaesthesia, Queen Elizabeth Hospital, South Australia, Australia; Discipline of Acute Care Medicine, University of Adelaide, South Australia, Australia; Basil Hetzel Institute, South Australia, Australia.
Department of Endocrinology and Diabetes, Queen Elizabeth Hospital, South Australia, Australia; School of Medicine, University of Adelaide, South Australia, Australia; College of Medicine and Public Health, Flinders University, South Australia, Australia.
Can J Diabetes. 2023 Apr;47(3):287-291. doi: 10.1016/j.jcjd.2022.12.003. Epub 2022 Dec 24.
Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are a class of oral glucose-lowering agents commonly used for the treatment of type 2 diabetes. With increased use, there has been an increase in the incidence of the rare but life-threatening complication of euglycemic diabetic ketoacidosis. A common but underappreciated precipitant is colonoscopy. In this work, we outline the pathophysiology of the interaction between colonoscopy and SGLT2i use, the evidence regarding SGLT2i use in the periprocedural setting and Australian Diabetes Society guidelines.
钠-葡萄糖共转运蛋白 2 抑制剂（SGLT2i）是一类常用的口服降糖药物，用于治疗 2 型糖尿病。随着使用的增加，罕见但危及生命的血糖正常的糖尿病酮症酸中毒并发症的发生率也有所增加。常见但未被充分认识的促发因素是结肠镜检查。在这项工作中，我们概述了结肠镜检查和 SGLT2i 使用之间相互作用的病理生理学、围手术期使用 SGLT2i 的证据以及澳大利亚糖尿病协会指南。
